Screening of a novel hepatic syndrome and its uses
AssigneeAssistance Publique-Hopitaux de Paris
InventorsRaoul Poupon, Brigitte Hermelin, Olivier Rosmorduc
Life of this patent
Estimating the term…
Loading patent…
AssigneeAssistance Publique-Hopitaux de Paris
InventorsRaoul Poupon, Brigitte Hermelin, Olivier Rosmorduc
Estimating the term…
The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from a nucleic acid sample extracted from peripheral blood mononucleate cells, heterozygous mutations of the MDR3 gene and/or homozygous mutations of the MDR3 gene that do not eliminate the expression of the protein expressed by the MDR3 gene, which has phosphatidylcholine carrier activity, in adult subjects associating cholesterol biliary microlithiasis and intrahepatic cholestasis.
A method of screening for a hepatic syndrome associated with one or more of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis, wherein said method comprises detecting in a sample of nucleic acid extracted from peripheral blood mononuclear cells of a subject, at least one heterozygous mutation of the MDR3 gene or at least one homozygous mutation of the MDR3 gene, or both, wherein said mutation or mutations do not destroy the expression of the protein expressed by said gene with phosphatidylcholine transporter activity, wherein the presence of said mutation or mutations in the nucleic acid of said subject is an indicator of susceptibility to said hepatic syndrome associated with one or more of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis.
A method of screening for a syndrome associated with one or more of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis, wherein said method comprises contacting a nucleic acid sample extracted from peripheral blood mononuclear cells of a subject with primers selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:13 and SEQ ID NO:15 through SEQ ID NO:66, wherein said contacting results in the identification of at least one mutation of the MDR3 gene and wherein said identification is an indicator of suceptibility to developing said syndrome.
A kit for the screening of a hepatic syndrome associated with at least one mutation of the MDR3 gene, wherein said kit comprises at least two primers selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:13 and SEQ ID NO:15 to SEQ ID NO:66.
A kit for evaluating a population at risk of developing a hepatic syndrome associated with at least one mutation of the MDR3 gene comprising, in addition to two primers selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13 or SEQ ID NO:15 to SEQ ID NO:66, reagents for assaying cholesterol and bile phospholipids.
A method of treating a patient having a syndrome associated with at least one of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis and at least one mutation of the MDR3 gene, wherein said method comprises administering to said patient a pharmaceutical composition comprising ursodeoxycholic acid.
Dependencies are inferred from the claim text.